Key Takeaways Real-world results with weight-loss drugs aren’t as impressive as those in clinical trialsClinic patients ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...

Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, ...

A new study published in the Obesity Journal found that anti-obesity injections may have a lesser impact on weight loss in a real-world context compared to clinical trials, as patients tend to ...

GLP-1 investors haven’t gained as much as expected from others’ losses. Since the FDA approved Wegovy, also known as ...

CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...

Back-to-back studies map complementary hunger and satiety pathways, offering clues to refine weight-loss drugs.

The New Science of Achieving a Healthy Weight” (Flatiron Books), former FDA Commissioner David A. Kessler argues that ultraprocessed foods — meaning ...